SecBot SecBot
DEFM14A ·Filed Aug 21, 2026

TBPH

Theravance Biopharma, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001104659-26-099364
Notable filing: DEFM14A
Actionable Insight ▲ Bullish

Traders should monitor the shareholder vote on September 18, 2026. The deal is fully financed and HSR cleared, so the primary risk is shareholder approval. If approved, shares will likely trade near $17.00 until close. The CVR is speculative and non-tradable, so its value is uncertain.

DirectionBullish
Confidencehigh
Horizonweeks

ampreloxetine

▼ Bearish Named in this DEFM14A
Impact
Phase
Phase 3 (failed)
Time to market
Not applicable. The drug failed all Phase 3 trials and development has been terminated.
Next catalyst
None dated

What to watchAmpreloxetine is a failed drug with no active development program. Theravance Biopharma (TBPH) was acquired by Zymeworks (ZYME) in a deal that closed September 2026, and TBPH shares were delisted. There are no upcoming catalysts for this drug. For investors, the relevant surviving public company is Zymeworks (ZYME), which acquired Theravance primarily for its commercial YUPELRI respiratory asset, not for ampreloxetine.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$17.01
T+0 close · Aug 21, 2026 · via day close
Latest settled
+0.24%
T+20 · $17.05
Vs SPY
+0.76%
α at T+20
Next horizon
T+60
due 17h ago
  1. T+0 · Aug 21 $17.01entry
  2. T+1 · 3mo ago 0.00%α +0.29% · $17.01
  3. T+5 · 3mo ago +0.24%α −0.24% · $17.05
  4. T+20 · 8w ago +0.24%α +0.76% · $17.05
  5. T+60 · due 17h ago Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Theravance Biopharma (TBPH) is being acquired by Zymeworks (ZYME) for $17.00 per share in cash plus one CVR per share, with the CVR entitling holders to 80% of net proceeds from any future monetization of ampreloxetine, a $50M milestone upon first commercial sale, and 10% royalties on net sales. The board unanimously recommends approval, and a fairness opinion from Lazard supports the consideration. The shareholder vote is scheduled for September 18, 2026, requiring a two-thirds majority, and the deal is expected to close in H2 2026.

Key Financial Metrics

Deal Value
$882.0M
Deal Type
merger

Key Facts

  • Shareholders to receive $17.00 per share in cash plus one CVR per share, representing contingent payments tied to ampreloxetine monetization.
  • CVR includes 80% of net proceeds from any license/divestiture of ampreloxetine within 10 years, a $50M milestone on first commercial sale, and 10% royalties on net sales.
  • Board of Directors unanimously recommends voting FOR the merger proposal.
  • Lazard rendered a fairness opinion that the per-share consideration is fair from a financial point of view.
  • Vote requires approval by holders of at least two-thirds of ordinary shares present and voting at the extraordinary general meeting on September 18, 2026.
  • HSR Act waiting period expired early on August 4, 2026; no other regulatory approvals mentioned as conditions.
  • Dissenting shareholders may seek fair value under Cayman Islands law, but must follow strict procedures.
  • Termination fee of $32,515,000 payable by either party under certain circumstances.
  • Financing committed via $350M senior secured notes from OMERS Life Sciences; no financing condition for closing.
  • Equity awards (options, RSUs, PSUs) will be cashed out at $17.00 per share plus CVRs; ESPP already suspended.

Financial Impact

Total equity value approximately $882M based on $17.00 per share and 51.9M shares outstanding; plus contingent CVR payments with uncertain value.

share pricedilutioncash consideration

Risk Factors

  • Shareholder vote may fail if two-thirds majority not achieved.
  • CVR payments are highly speculative and may never materialize; Parent has no obligation to pursue ampreloxetine monetization.
  • Potential litigation or appraisal actions could delay closing.
  • Termination fee of $32.5M may not fully compensate if deal fails.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
55% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
DEFM14A Filing (Primary)0001104659-26-099364
Document: tm2621435-2_defm14a.htm0001104659-26-099364

Track record

12 reports on TBPH

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +2.11% at T+1 after the Mar 3, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry price pending
  2. Oct 5, 20266w ago 15-12G Bearish 7/10 No price data
  3. Sep 25, 20267w ago SC 13D/A Neutral 4/10 Entry $17.04 No price data
  4. Sep 23, 20267w ago 25-NSE Bearish 7/10 Entry $17.05 No price data
  5. Aug 25, 202611w ago DEFA14A Neutral 4/10 Entry $17.03 to $17.03 · 0.00% −0.23% vs SPY
  6. Aug 21, 202612w ago DEFM14A Bullish 7/10 Viewing Entry $17.01 to $17.05 ▲ +0.24% +0.76% vs SPY
  7. Aug 11, 202613w ago PREM14A Bullish 7/10 Entry $16.91 to $17.06 ▲ +0.89% +1.95% vs SPY
  8. Aug 10, 202614w ago 8-K Bullish 7/10 Entry $16.91 to $17.06 ▲ +0.89% +1.80% vs SPY
  9. Jun 29, 202620w ago 8-K Bullish 7/10 Entry $17.06 to $16.86 ▼ −1.17% −0.89% vs SPY
  10. Jun 23, 202620w ago 8-K Neutral 2/10 Entry $17.27 to $16.81 ▼ −2.66% −4.60% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 9h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 21, 2026